Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 1854.

https://doi.org/10.1182/blood-2024-203053

Published: 2024

Journal Articles

Prevalence and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Chronic Lymphocytic Leukemia and Richter Transformation

Blood (2024) 144 (Supplement 1): 762.

https://doi.org/10.1182/blood-2024-194469

Published: 2024

Journal Articles

Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs

Blood (2021) 137 (25): 3507–3517.

https://doi.org/10.1182/blood.2020008201

Published: 2021

Includes: Supplemental data

Journal Articles

Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs

Blood (2019) 134 (Supplement_1): 3044.

https://doi.org/10.1182/blood-2019-125530

Published: 2019

Journal Articles

Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia

Valentina Griggio, Candida Vitale, MD PhD, Chiara Salvetti, MD, Francesca Romana Mauro, MD, Daniela Pietrasanta, MD, Iolanda Donatella Vincelli, Lydia Scarfo, MD, Giovanni Del Poeta, MD, Gianluca Gaidano, MD PhD, Valter Gattei, MD, Robin Foà, MD, Mario Boccadoro, Marta Coscia, MD PhD

Blood (2019) 134 (Supplement_1): 3031.

https://doi.org/10.1182/blood-2019-125617

Published: 2019

Journal Articles

Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia

Valentina Griggio, Candida Vitale, MD, Maria Todaro, PhD, Francesca Romana Mauro, Chiara Salvetti, MD, Daniela Pietrasanta, Iolanda Donatella Vincelli, MD, Lydia Scarfo, MD, Giovanni Del Poeta, MD, Gianluca Gaidano, MD PhD, Valter Gattei, MD, Robin Foà, MD, Mario Boccadoro, MD, Marta Coscia, MD

Blood (2018) 132 (Supplement 1): 4412.

https://doi.org/10.1182/blood-2018-99-116068

Published: 2018

Journal Articles

Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance

Maria Todaro, PhD, Valentina Griggio, Ms, Candida Vitale, MD, Chiara Salvetti, MD, Chiara Riganti, MD, Mario Boccadoro, MD, Yosef Landesman, PhD, Marta Coscia, MD PhD

Blood (2016) 128 (22): 3210.

https://doi.org/10.1182/blood.V128.22.3210.3210

Published: 2016

Journal Articles

HIF-1α Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target

Blood (2016) 128 (22): 305.

https://doi.org/10.1182/blood.V128.22.305.305

Published: 2016

Journal Articles

The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance

Valentina Griggio, Ms, Candida Vitale, MD, Chiara Riganti, MD, Joanna Kopecka, PhD, Michele Dal Bo, Davide Rossi, MD PhD, Gabriele Pozzato, MD, Luca Laurenti, MD, Francesco Zallio, MD, Monia Marchetti, MD PhD, Marina Ruggeri, Paola Omedè, Giovanni Del Poeta, Pr, MD, Valter Gattei, MD, Gianluca Gaidano, MD PhD, Mario Boccadoro, MD, Massimo Massaia, MD, Marta Coscia, MD PhD

Blood (2015) 126 (23): 2925.

https://doi.org/10.1182/blood.V126.23.2925.2925

Published: 2015

Journal Articles

The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells

Candida Vitale, MD, Valentina Griggio, MS, Chiara Riganti, MD, Ivana Campia, PhD, Marta Robino, MD, Micol Rigoni, PhD, Patrizia Sciancalepore, MD, Myriam Foglietta, MD PhD, Barbara Castella, PhD, Mario Boccadoro, MD, Massimo Massaia, Marta Coscia, MD PhD

Blood (2014) 124 (21): 833.

https://doi.org/10.1182/blood.V124.21.833.833

Published: 2014

Journal Articles

Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA)

Marta Coscia, MD, PhD, Valentina Griggio, Michela Capello, PhD, Candida Vitale, MD, Federica Linty, PhD, Paola Cappello, PhD, Giorgia Mandili, PhD, Barbara Castella, PhD, Myriam Foglietta, MD, Micol Rigoni, PhD, Patrizia Sciancalepore, MD, Marta Robino, Marina Ruggeri, PhD, Daniela Drandi, PhD, Paola Omedè, PhD, Marco Ladetto, MD, Francesco Novelli, MD, Mario Boccadoro, MD, Massimo Massaia, MD

Blood (2012) 120 (21): 3878.

https://doi.org/10.1182/blood.V120.21.3878.3878

Published: 2012

Journal Articles

The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL)

Marta Coscia, MD, PhD, Micol Rigoni, PhD, Chiara Riganti, MD, Candida Vitale, MD, Ivana Campia, PhD, Valentina Griggio, PhD, Myriam Foglietta, MD, Barbara Castella, PhD, Patrizia Sciancalepore, MD, Maria Elisa Canepari, MD, Marta Robino, Daniela Drandi, PhD, Marco Ladetto, MD, Amalia Bosia, MD, Mario Boccadoro, MD, Massimo Massaia, MD

Blood (2012) 120 (21): 3881.

https://doi.org/10.1182/blood.V120.21.3881.3881

Published: 2012

Journal Articles

Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells

Marta Coscia, Candida Vitale, Silvia Peola, Myriam Foglietta, Micol Rigoni, Valentina Griggio, Barbara Castella, Daniela Angelini, Sabina Chiaretti, Chiara Riganti, Anna Guarini, Daniela Drandi, Marco Ladetto, Amalia Bosia, Robin Foà, Luca Battistini, Mario Boccadoro, Jean-Jacques Fournié, Massimo Massaia

Blood (2012) 120 (16): 3271–3279.

https://doi.org/10.1182/blood-2012-03-417519

Published: 2012

Includes: Supplemental data

Journal Articles

The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells

Marta Coscia, MD, PhD, Micol Rigoni, PhD, Chiara Riganti, MD, Ivana Campia, PhD, Candida Vitale, MD, Valentina Griggio, PhD, Silvia Peola, PhD, Barbara Castella, PhD, Patrizia Sciancalepore, MD, Daniela Drandi, PhD, Marco Ladetto, MD, Amalia Bosia, MD, Mario Boccadoro, MD, Massimo Massaia, MD

Blood (2011) 118 (21): 735.

https://doi.org/10.1182/blood.V118.21.735.735

Published: 2011

Journal Articles

Identification by Serological Proteome Analysis (SERPA) of Tumor-Associated Antigens Eliciting Antibody Responses In Chronic Lymphocytic Leukemia (CLL)

Marta Coscia, MD, PhD, Michela Capello, PhD, Valentina Griggio, PhD, Federica Linty, PhD, Candida Vitale, MD, Silvia Peola, PhD, Barbara Castella, PhD, Micol Rigoni, PhD, Daniela Drandi, PhD, Marina Ruggeri, PhD, Paola Omedè, PhD, Marco Ladetto, MD, Franco Novelli, MD, Mario Boccadoro, MD, Massimo Massaia, MD

Blood (2010) 116 (21): 917.

https://doi.org/10.1182/blood.V116.21.917.917

Published: 2010

NARROW

Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia

Prevalence and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Chronic Lymphocytic Leukemia and Richter Transformation

Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs

Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs

Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia

Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia

Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance

HIF-1α Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target

The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance

The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells

Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA)

The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL)

Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells

The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells

Identification by Serological Proteome Analysis (SERPA) of Tumor-Associated Antigens Eliciting Antibody Responses In Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only